| Date Filed | Type | Description |
| 08/14/2023 |
4
| Klassen Preston (President & Head of R & D) has filed a Form 4 on Regulus Therapeutics Inc.|
Txns:
| Granted 225,000 options to buy
@ $1.36, valued at
$306k
|
|
| 06/12/2023 |
4
| Klassen Preston (President & Head of R & D) has filed a Form 4 on Regulus Therapeutics Inc.|
Txns:
| Granted 350,000 options to buy
@ $1.46, valued at
$511k
|
|
| 06/12/2023 |
3
| Klassen Preston (President & Head of R & D) has filed a Form 3 on Regulus Therapeutics Inc. |
| 03/24/2023 |
4
| Klassen Preston (Director) has filed a Form 4 on Metacrine, Inc.|
Txns:
| Granted 842,211 shares
@ $0.47, valued at
$395.8k
Disposed/sold 842,211 options to buy
@ $0.47, valued at
$395.8k
|
|
| 03/21/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 01/27/2023 |
4
| Klassen Preston (President & CEO) has filed a Form 4 on Metacrine, Inc.|
Txns:
| Sold 380,605 shares
@ $0.4132, valued at
$157.3k
|
|
| 04/20/2022 |
4
| Klassen Preston (President & CEO) has filed a Form 4 on Metacrine, Inc.|
Txns:
| Sold 43,575 shares
@ $0.5021, valued at
$21.9k
Sold 1,173 shares
@ $0.5056, valued at
$593.1 |
|
| 04/18/2022 |
4
| Klassen Preston (President & CEO) has filed a Form 4 on Metacrine, Inc.|
Txns:
| Granted 104,500 shares
@ $0 |
|
| 03/01/2022 |
4
| Klassen Preston (President & CEO) has filed a Form 4 on Metacrine, Inc.|
Txns:
| Granted 842,211 shares
@ $0
Granted 842,211 options to buy
@ $0.47, valued at
$395.8k
|
|
| 05/20/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/12/2021 |
4
| Klassen Preston (President & CEO) has filed a Form 4 on Metacrine, Inc.|
Txns:
| Granted 247,500 options to buy
@ $10.09, valued at
$2.5M
|
|
| 09/15/2020 |
3
| Klassen Preston (President & CEO) has filed a Form 3 on Metacrine, Inc. |
| 03/03/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/16/2019 |
4
| Klassen Preston (EVP and CMO) has filed a Form 4 on ARENA PHARMACEUTICALS INC|
Txns:
| Paid exercise price by delivering 2,309 shares
@ $47.32, valued at
$109.3k
Exercised 6,300 options to buy
@ $0 |
|
| 07/01/2019 |
4
| Klassen Preston (Director) has filed a Form 4 on Conatus Pharmaceuticals Inc.|
Txns:
| Granted 20,000 options to buy
@ $0.29, valued at
$5.8k
|
|
| 01/08/2019 |
4
| Klassen Preston (EVP and CMO) has filed a Form 4 on ARENA PHARMACEUTICALS INC|
Txns:
| Sold 15,600 shares
@ $41.6756, valued at
$650.1k
Sold 400 shares
@ $42.3175, valued at
$16.9k
Sold 3,000 shares
@ $44, valued at
$132k
Granted 75,000 options to buy
@ $40.94, valued at
$3.1M
Granted 12,600 options to buy
@ $0
Exercised 16,000 options to buy
@ $15.1, valued at
$241.6k
Exercised 3,000 options to buy
@ $15.1, valued at
$45.3k
|
|
| 06/25/2018 |
4
| Klassen Preston (Director) has filed a Form 4 on Conatus Pharmaceuticals Inc.|
Txns:
| Granted 20,000 options to buy
@ $4.99, valued at
$99.8k
|
|
| 01/22/2018 |
4
| Klassen Preston (EVP and CMO) has filed a Form 4 on ARENA PHARMACEUTICALS INC|
Txns:
| Granted 130,000 options to buy
@ $35.6, valued at
$4.6M
|
|
| 06/26/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 03/20/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 03/20/2017 |
3
| Form 3 - Initial statement of beneficial ownership of securities |
| 06/24/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 02/04/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 07/29/2013 |
4
| Klassen Preston (SVP, Head Global Development) has filed a Form 4 on Orexigen Therapeutics, Inc.|
Txns:
| Sold 71,229 shares
@ $7.16, valued at
$510k
Exercised 71,229 options to buy
@ $1.66, valued at
$118.2k
|
|
| 02/19/2013 |
4
| Klassen Preston (SVP, Head Global Development) has filed a Form 4 on Orexigen Therapeutics, Inc.|
Txns:
| Granted 245,000 options to buy
@ $5.69, valued at
$1.4M
|
|
| 01/26/2012 |
4
| Klassen Preston (SVP, Head Global Development) has filed a Form 4 on Orexigen Therapeutics, Inc.|
Txns:
| Granted 350,000 options to buy
@ $2.58, valued at
$903k
|
|
| 07/26/2011 |
4
| Klassen Preston (SVP, Head Global Development) has filed a Form 4 on Orexigen Therapeutics, Inc.|
Txns:
| Granted 832,000 options to buy
@ $1.66, valued at
$1.4M
Disposed/sold 200,000 options to buy
@ $7.52, valued at
$1.5M
Disposed/sold 30,000 options to buy
@ $6.74, valued at
$202.2k
Disposed/sold 45,000 options to buy
@ $2.94, valued at
$132.3k
Disposed/sold 107,000 options to buy
@ $2.94, valued at
$314.6k
Disposed/sold 450,000 options to buy
@ $1.7, valued at
$765k
|
|
| 03/04/2011 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 09/22/2010 |
4
| Klassen Preston (SVP, Head Global Development) has filed a Form 4 on Orexigen Therapeutics, Inc.|
Txns:
| Granted 45,000 options to buy
@ $5.89, valued at
$265.1k
|
|
| 06/01/2010 |
3
| Form 3 - Initial statement of beneficial ownership of securities |